Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry - Hardcover

Gassmann, Oliver; Reepmeyer, Gerrit; Zedtwitz, Maximilian Von

Hardcover

ISBN 10: 3540407170 ISBN 13: 9783540407171

Publisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 2004

Synopsis

The pharmaceutical industry is in a dire situation: R&D still produces no more drugs than 10 years ago, while costs have quadrupled in the meantime. Little advances have been made in innovation efficiency. Worse yet, drug development times are unacceptably long, possible drug development targets are waning, and national healthcare is tightening the cost squeeze. A predictable and efficient pipeline of drug candidates, coupled with a handful of blockbuster drugs, is considered the Holy Grail of pharmaceutical innovation. In this book, the authors develop a case for mastering pharmaceutical innovation focusing on three leading sources of future pharmaceutical competitiveness: new technologies and techniques, better pipeline management, and stronger integration of external innovation. Illustrated with plenty of real-life cases, this book tells you how to put the principles of leading pharmaceutical innovation into practice.

About this title

Review

From the reviews:

"This book examines the international pharmaceutical industry with special emphasis on the current and emerging research methodologies a ] . What distinguishes this book from others on the same subject is its emphasis on empirical findings (53 figures, 20 tables) and an exceptionally good, if short, discussion of various research technologies a ] . The six-page glossary of industry terms, when used with its decent index, is a particular joy. a ] recommend this offering to prospective managers and researchers in this industry a ] ." (Robert R. Rothberg, Journal of Product Innovation Management, Vol. 22, 2005)

From the Back Cover

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.  

"One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals."

Dr. Daniel Vasella, CEO, Novartis International

"Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry."

Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley  

"It´s time for a paradigm shift in pharmaceutical R&D. This book will tell you why."

Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany) 

"This book offers a fact based, comprehensive insight to the increasing challenges of today`s drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture".

Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma 

  

Edition details

• Publisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
• Publication date: 2004
• Language: English
• ISBN 10: 3540407170
• ISBN 13: 9783540407171
• Binding: Hardcover
• Edition number: 1
• Number of pages: 189